Cas:607-96-5 5-methyl-4-(4-nitrophenylazo)resorcinol manufacturer & supplier

We serve Chemical Name:5-methyl-4-(4-nitrophenylazo)resorcinol CAS:607-96-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-methyl-4-(4-nitrophenylazo)resorcinol

Chemical Name:5-methyl-4-(4-nitrophenylazo)resorcinol
CAS.NO:607-96-5
Synonyms:1,3-Benzenediol, 5-methyl-4-[(E)-2-(4-nitrophenyl)diazenyl]-;5-methyl-4-(4-nitrophenylazo)resorcinol;5-Methyl-4-[(E)-(4-nitrophenyl)diazenyl]benzene-1,3-diol;1,3-Benzenediol, 5-methyl-6-((4-nitrophenyl)azo)-;1,3-Benzenediol, 5-methyl-4-((4-nitrophenyl)azo)-;2,4-Dihydroxy-6-methyl-4′-nitroazobenzene;4-nitrobenzene-azo-orcinol;5-Methyl-4-[(E)-(4-nitrophenyl)diazenyl]-1,3-benzenediol;5-Methyl-6-((p-nitrophenyl)azo)resorcinol;EINECS 210-150-0;Resorcinol, 5-methyl-6-((p-nitrophenyl)azo)-
Molecular Formula:C13H11N3O4
Molecular Weight:273.244
HS Code:2927000090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:514.8±45.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.651
PSA:111.00000
Exact Mass:273.074951
LogP:3.28

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,3-Benzenediol, 5-methyl-4-[(E)-2-(4-nitrophenyl)diazenyl]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Resorcinol, 5-methyl-6-((p-nitrophenyl)azo)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dihydroxy-6-methyl-4′-nitroazobenzene Use and application,1,3-Benzenediol, 5-methyl-4-((4-nitrophenyl)azo)- technical grade,usp/ep/jp grade.


Related News: Our COVID-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. 1-[(2-methylpropan-2-yl)oxy]propan-2-ol manufacturers In SLE, along with the pivotal TULIP phase III programme, anifrolumab continues to be evaluated in a long-term extension phase III trial.12 A phase II trial of anifrolumab in SLE using subcutaneous delivery has been completed. 7-Bromo-4-chloro-1H-pyrrolo[3,2-c]pyridine suppliers The therapy is designed to treat ADA-SCID, a genetic condition in which children are born without a properly functioning immune system. 4-(2,4-dimethoxyphenyl)-1,3-thiazol-2-amine vendor & factory.